SSII SS Innovations International, Inc.

Nasdaq Surgical & Medical Instruments & Apparatus FL CIK: 0001676163
AI RATING
SELL
88% Confidence

Investment Thesis

SSII exhibits severe fundamental weakness with stagnant revenue (0% YoY growth), deep operating losses (-32.8% margin), and negative operating cash flow (-$2.3M annually). Despite marginal YoY profitability improvements and healthy 48% gross margins, the company remains fundamentally unprofitable and is burning cash unsustainably against a depleting $16M reserve base.

Strengths

  • + Strong gross margin of 48% demonstrates viable core product economics
  • + Excellent near-term liquidity with 2.54x current ratio and $16M cash on balance sheet
  • + Clean balance sheet with zero long-term debt and no debt service burden

Risks

  • ! Complete revenue stagnation at 0% YoY growth indicating lack of market traction or demand
  • ! Severe operating losses (-32.8% margin) with -$3.6M operating loss proving core business is unprofitable
  • ! Negative operating cash flow of -$2.3M annually consuming ~14% of cash reserves annually at unsustainable pace

Key Metrics to Watch

Financial Metrics

Revenue
11.1M
Net Income
-3.6M
EPS (Diluted)
$-0.02
Free Cash Flow
-2.4M
Total Assets
90.5M
Cash
16.0M

Profitability Ratios

Gross Margin 48.0%
Operating Margin -32.8%
Net Margin -32.3%
ROE -6.6%
ROA -4.0%
FCF Margin -21.3%

Balance Sheet & Liquidity

Current Ratio
2.54x
Quick Ratio
1.89x
Debt/Equity
0.00x
Debt/Assets
39.8%
Interest Coverage
-83.54x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: 2026-05-15T10:11:27.354908 | Data as of: 2026-03-31 | Powered by Claude AI